Care and cost benefits of Castlights GLP-1 & Weight Management Program GLP-1 medications have generated massive interest as powerful tools for weight loss and managing conditions like type 2 diabetes
A new study suggests that individuals taking popular new GLP-1 receptor agonist drugs, such as Ozempic, Wegovy and Mounjaro, face an increased risk of nausea, vomiting and other stomach problems, especially when taking higher doses of the medication
Osmotic laxatives such as macrogol (polyethylene glycol) are often considered first-line for chronic constipation on GLP-1 therapy, as they draw water into the bowel to soften stools
That dynamic shifted in 2024, when Wegovy gained an indication for reduced cardiovascular risk in March and Zepbound added an OSA indication in December
[1] [2] However, the published data do not provide detailed week-by-week fatigue timelines, and retatrutide-specific evidence on the precise duration of tiredness remains limited
Retatrutide and Tirzepatide: Retatrutide and Tirzepatide are newer additions to the GLP-1 analogue family and are currently under investigation in clinical trials for obesity treatment
